Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672159 | 0.77 | TLR8 (0.33) | NPSR1ALDH1A1MAPTTLR8TLR7 | |
| SCHEMBL22281770 | 0.77 | TRIM58 (0.34) | — | |
| SCHEMBL12303153 | 0.76 | KDM4E (0.32) | — | |
| SCHEMBL2371941 | 0.75 | MAP2K7 (0.30) | MAP2K7 | |
| SCHEMBL12303154 | 0.75 | PDK2 (0.36) | MAP2K7 | |
| SCHEMBL30329676 | 0.75 | YTHDC1 (0.46) | ALDH1A1MAPT | |
| SCHEMBL9287279 | 0.75 | TLR8 (0.53) | ALDH1A1TLR8TLR7 | |
| SCHEMBL10267528 | 0.73 | PDE10A (0.41) | NPSR1ALDH1A1MAPT | |
| SCHEMBL11916234 | 0.73 | TLR8 (0.43) | NPSR1ALDH1A1TLR8TLR7 | |
| SCHEMBL77166 | 0.73 | LMNA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-10875885-B2 | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200331956-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | Atea Pharmaceuticals, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20140194444-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-10 | — | — | US | disclosed |
| US-8664219-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-04 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8426425-B2 | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110224197-A1 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-15 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110020376-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-7691853-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | US | disclosed |
| US-7390815-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070270444-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020376-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKDC, MAP3K5, MAP3K20 | NPSR1 4594/4885ALDH1A1 2841/4885MAPT 1503/4885 |
| US-20140194444-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKDC, MAP3K5, MAP3K20 | NPSR1 4594/4885ALDH1A1 2841/4885MAPT 1503/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | NPSR1 3479/4885ALDH1A1 4768/4885MAPT 383/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | NPSR1 2839/4885ALDH1A1 2718/4885MAPT 3444/4885 |
| US-20110224197-A1 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | GSK3B, CDK3, GSK3A | NPSR1 4321/4885ALDH1A1 4707/4885MAPT 165/4885 |
| US-20070270444-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, CDK3, GSK3A | NPSR1 3425/4885ALDH1A1 4625/4885MAPT 314/4885 |
| US-20200331956-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | NPSR1 2755/4885ALDH1A1 1397/4885MAPT 3735/4885 |
| US-10875885-B2 | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | NPSR1 2493/4885ALDH1A1 1295/4885MAPT 3365/4885 |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MAVS, TLR3, DDX18 | NPSR1 2869/4885ALDH1A1 2726/4885MAPT 4443/4885 |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | PNP, SLC29A2, NT5C2 | NPSR1 3175/4885ALDH1A1 495/4885MAPT 4520/4885 |
| US-20100022507-A1 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K20, PRKDC | NPSR1 4589/4885ALDH1A1 3071/4885MAPT 1250/4885 |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | PNP, SLC29A2, NT5C2 | NPSR1 3328/4885ALDH1A1 426/4885MAPT 4565/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | NPSR1 3513/4885ALDH1A1 1171/4885MAPT 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.